The Business Brew

Current Events - uniQure and the FDA

Mar 6, 2026
Professor Sarah Tabrizi, neurologist and Huntington's researcher, and Dr. Victor Sung, clinician-researcher on AMT-130, discuss AMT-130 gene therapy delivery and trial design. They debate use of EnrollHD as a propensity-matched external control, surgical and imaging details, ethical issues around long blinding, FDA skepticism, and regulatory pathways.
Ask episode
AI Snips
Chapters
Transcript
Episode notes
INSIGHT

Trial Design Split Between US And Europe

  • Unicure ran low- and high-dose cohorts with a partial-burr-hole placebo in the US but Europe rejected a placebo arm, so European sites ran open-label.
  • The US placebo subjects were offered treatment after 12 months and four accepted, limiting long-term internal controls.
INSIGHT

EnrollHD As The External Comparator

  • EnrollHD is a large longitudinal external registry (~33,000 participants) used to create propensity-score matched external controls for AMT-130.
  • EnrollHD lacks MRI imaging but provides motor, cognitive, and functional data useful for matched comparisons.
INSIGHT

Pre specified 36 Month Analysis Using Propensity Matching

  • Sarah Tabrizi and team pre-specified a 36-month pivotal analysis comparing AMT-130 to propensity-matched EnrollHD external controls, approved in advance by FDA initially.
  • They argue propensity matching is an accepted rare-disease method when randomized long-term sham is unethical or impractical.
Get the Snipd Podcast app to discover more snips from this episode
Get the app